ADA-011 / Adanate - LARVOL DELTA

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=46 | Terminated | Sponsor: Adanate, Inc | Active, not recruiting ➔ Terminated; Internal company decision (non-safety related)

Checkpoint inhibition • Monotherapy • Trial termination • Oncology • Solid Tumor

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Adanate, Inc | Recruiting ➔ Active, not recruiting | N=90 ➔ 45 | Trial completion date: Dec 2025 ➔ Dec 2024

Checkpoint inhibition • Combination therapy • Enrollment change • Enrollment closed • Metastases • Monotherapy • Trial completion date • Oncology • Solid Tumor

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Adanate, Inc | Not yet recruiting ➔ Recruiting

Checkpoint inhibition • Combination therapy • Enrollment open • Metastases • Monotherapy • Oncology • Solid Tumor

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=90 | Not yet recruiting | Sponsor: Adanate, Inc

Checkpoint inhibition • Combination therapy • Monotherapy • New P1 trial • Oncology • Solid Tumor